Clinical-stage biopharmaceutical company developing vaccines and therapeutics for infectious diseases and cancer.
Altimmune, Inc., headquartered in Gaithersburg, Maryland, is a clinical-stage biopharmaceutical company specializing in the development of innovative treatments for obesity and liver diseases. The company is advancing a diverse pipeline of therapeutic candidates aimed at addressing significant unmet medical needs. One of its leading products under development is pemvidutide (proposed INN, formerly ALT-801), a dual GLP-1/glucagon receptor agonist currently in Phase 1b trials for the treatment of obesity and non-alcoholic steatohepatitis (NASH).
In addition to pemvidutide, Altimmune is actively developing HepTcell, an immunotherapeutic product targeting patients chronically infected with the hepatitis B virus (HBV). This promising candidate is currently in Phase 2 clinical trials, underscoring Altimmune's commitment to combating liver diseases through innovative immunotherapy approaches.
Originally founded as Vaxin Inc. in 1997, Altimmune rebranded itself in September 2015 to reflect its expanded focus on advancing transformative therapies in biopharmaceuticals. The company's strategic pivot has enabled it to build a robust pipeline and foster strategic collaborations to accelerate the development and commercialization of its cutting-edge treatments.
Altimmune's location in Maryland, a hub for biotechnology and pharmaceutical innovation, positions it strategically within the biotech community. With a dedicated team and a strong commitment to scientific excellence, Altimmune continues to drive forward its mission of pioneering therapies that improve patient outcomes in obesity and liver diseases globally.